PROCEPT® BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and full year ended December 31, 2021.
Recent Highlights
Revenue of $10.1 million for the fourth quarter of 2021 and $34.5 million for the full year of 2021, compared to $3.2 million and $7.7 million, respectively, from the same periods of 2020
U.S. system and rental revenue of $5.0 million for the fourth quarter of 2021, compared to $1.2 million in the prior year period
U.S. handpiece and consumables revenue of $3.4 million for the fourth quarter of 2021, compared to $0.8 million in the prior year period
Announced positive 5-year WATER Study data on February 14, 2022
Issued 2022 total revenue guidance range of $54.0 million to $58.0 million
“We are very pleased with the results we delivered in 2021 and continue to see positive momentum in the first quarter of 2022,” said Reza Zadno, Chief Executive Officer. “We also achieved a number of critical milestones over the last few months, including approximately doubling the size of our field-based sales force and announcing 5-year WATER Study data - which highlights the durability, safety and efficacy of Aquablation therapy and demonstrates IPSS superiority compared to TURP in prostates larger than 50 mL. We believe these catalysts will accelerate the adoption of our technology to become the standard of care for BPH.”
https://finance.yahoo.com/news/procept-biorobotics-reports-fourth-quarter-120000128.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.